Pfizer Pregabalin Approved For Marketing In Europe; FDA Review Continues
This article was originally published in The Pink Sheet Daily
Executive Summary
The Neurontin follow-on is approved in the EU for neuropathic pain and as add-on therapy for partial seizures in patients with epilepsy. FDA's user fee deadline for pregabalin (Lyrica) is Oct. 30; Neurontin (gabapentin) generics could hit the market prior to pregabalin's approval.